Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, Hamburg, Germany.
Institute of Medical Biometry and Epidemiology, Hamburg, Germany.
Br J Anaesth. 2021 Feb;126(2):516-524. doi: 10.1016/j.bja.2020.09.051. Epub 2020 Nov 20.
This RCT investigated the effect of opioid titration by three different nociception monitoring devices or clinical signs during general anaesthesia.
Ninety-six patients undergoing radical retropubic prostatectomy with propofol/remifentanil anaesthesia were randomised into one of four groups to receive remifentanil guided by one of three nociception monitoring devices (surgical pleth index [SPI], pupillary pain index [PPI], or nociception level [NOL]) or by clinical judgement (control). Intraoperative remifentanil requirement was the primary endpoint, whereas recovery parameters and stress hormone levels were secondary endpoints.
The mean [95% confidence interval {CI}] remifentanil administration rate differed between the groups: control 0.34 (0.32-0.37), SPI 0.46 (0.38-0.55), PPI 0.07 (0.06-0.08), and NOL 0.16 (0.12-0.21) μg kg min(P<0.001). Intraoperative cessation of remifentanil administration occurred in different numbers (%) of patients: control 0 (0%), SPI 1 (4.3%), PPI 18 (75.0%), and NOL 11 (47.8%); P=0.002. The area under the curve analyses indicated differences in cumulative cortisol levels (mg L min) amongst the groups: control 37.9 (33.3-43.1), SPI 38.6 (33.8-44.2), PPI 72.1 (63.1-82.3), and NOL 54.4 (47.6-62.1) (mean [95% CI]). Pairwise group comparison results were as follows: control vs SPI, P=0.830; control vs PPI, P<0.001; control vs NOL, P=0.001; SPI vs PPI, P<0.001; SPI vs NOL, P=0.002; and PPI vs NOL, P=0.009.
The nociception monitoring devices and clinical signs reflect the extent of nociception differently, leading to dissimilar doses of remifentanil. Very low remifentanil doses were associated with an increase and higher remifentanil doses were accompanied by a decrease in serum cortisol concentrations. Use of nociception monitoring devices for guiding intra-operative opioid dosing needs further validation.
NCT03380949.
本 RCT 研究了在全身麻醉期间通过三种不同的伤害感受监测设备或临床体征进行阿片类药物滴定的效果。
96 例接受丙泊酚/瑞芬太尼麻醉行根治性前列腺切除术的患者被随机分为四组之一,以接受三种伤害感受监测设备之一(手术 pleth 指数[SPI]、瞳孔疼痛指数[PPI]或伤害感受水平[NOL])或临床判断(对照)指导的瑞芬太尼。术中瑞芬太尼的需求量为主要终点,而恢复参数和应激激素水平为次要终点。
各组间的平均(95%置信区间[CI])瑞芬太尼给药率不同:对照组 0.34(0.32-0.37)、SPI 0.46(0.38-0.55)、PPI 0.07(0.06-0.08)和 NOL 0.16(0.12-0.21)μg kg min(P<0.001)。术中停止瑞芬太尼给药的患者数量不同(%):对照组 0(0%)、SPI 1(4.3%)、PPI 18(75.0%)和 NOL 11(47.8%);P=0.002。累积皮质醇水平(mg L min)的曲线下面积分析显示各组之间存在差异:对照组 37.9(33.3-43.1)、SPI 38.6(33.8-44.2)、PPI 72.1(63.1-82.3)和 NOL 54.4(47.6-62.1)(均值[95%CI])。组间两两比较结果如下:对照组与 SPI,P=0.830;对照组与 PPI,P<0.001;对照组与 NOL,P=0.001;SPI 与 PPI,P<0.001;SPI 与 NOL,P=0.002;PPI 与 NOL,P=0.009。
伤害感受监测设备和临床体征对伤害感受的反映程度不同,导致瑞芬太尼的剂量不同。非常低的瑞芬太尼剂量与血清皮质醇浓度的增加有关,而较高的瑞芬太尼剂量则与皮质醇浓度的降低有关。使用伤害感受监测设备指导术中阿片类药物的剂量需要进一步验证。
NCT03380949。